Segment Information (Tables)

12 Months Ended

Mar. 31, 2024

Schedule Of Company Revenue and Adjusted EBITDA by Segment

The Company’s revenue and Adjusted EBITDA by segment is as follows:


	Year Ended March 31,
	2024		2023		2022
	(in thousands)
Segment Revenue: (1)
Consumer and Research Services	$	219,638	$	299,489	$	271,893
Total revenue	$	219,638	$	299,489	$	271,893
Segment Adjusted EBITDA:
Consumer and Research Services Adjusted EBITDA	$	(36,769)	$	(17,997)	$	(30,112)
Therapeutics Adjusted EBITDA	(91,025)		(88,503)		(76,944)
Unallocated Corporate (2)	(48,002)		(54,801)		(43,684)
Total Adjusted EBITDA	$	(175,796)	$	(161,301)	$	(150,740)
Reconciliation of net loss to Adjusted EBITDA:
Net loss	$	(666,704)	$	(311,656)	$	(217,490)
Adjustments
Interest income, net	(14,331)		(9,676)		(277)
Other (income) expense, net	(506)		93		83
Change in fair value of warrant liabilities	—		—		(32,989)
Provision for (benefit from) income taxes	73		(2,772)		(3,480)
Depreciation and amortization	18,033		20,239		18,899
Amortization of acquired intangible assets	11,448		16,486		7,269
Impairment of acquired intangible assets	—		9,968		—
Stock-based compensation expense	120,209		116,017		57,933
Acquisition-related costs (3)	—		—		9,362
Litigation settlement, net (4)	98		—		9,950
Loss on disposition of Lemonaid Health Limited and transaction-related costs (5)	2,375		—		—
Goodwill impairment (6)	351,744		—		—
Cybersecurity incident expenses, net of probable insurance recoveries (7)	1,765		—		—
Total Adjusted EBITDA	$	(175,796)	$	(161,301)	$	(150,740)

(1)All product and service revenue is associated with the Consumer and Research Services segment and there was no Therapeutics revenue for the fiscal years ended March 31, 2024, 2023 and 2022.

(2)Certain expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.

(3)For the fiscal year ended March 31, 2022, acquisition-related costs primarily consisted of advisory, legal and consulting fees.

(4)Litigation settlement, net is litigation cost net of probable insurance recoveries, which is not expected to occur on a recurring basis and not part of the Company's normal and continued business activity.

(5)Refer to Note 19, “Disposition of Subsidiary” for additional information.

(6)Refer to Note 10, “Balance Sheet Components — Goodwill” for additional information.

(7)Refer to Note 13, “Commitments and Contingencies — Cybersecurity Incident” for additional information.

Summary of Customers Accounting for 10% or More of Segment Revenues

Customers accounting for 10% or more of segment revenues were as follows:


	Year Ended March 31,
	2024				2023				2022
	(in thousands, except percentages)
Consumer and Research Services Segment Revenue:
Customer C (1) (2)	$	48,325	22	%	$	65,721	22	%	$	53,875	20	%
Customer B (3)	$	11,753	5	%	$	47,448	16	%	$	46,064	17	%

(1)Customer C is a reseller

(2)Customer C revenues are primarily in the United States.

(3)Customer B revenues are in the U.K.